

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

## Macugen (pegaptanib)

CG-DRUG-90

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Macugen (pegaptanib)

### APPROVAL CRITERIA

Requests for Macugen (pegaptanib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of established neovascular (“Wet”) age-related macular degeneration.

Request for Macugen (pegaptanib) may **not** be approved for all other conditions including, but not limited to:

- I. Diabetic eye disease
- II. As treatment of other forms of age-related macular degeneration to prevent progression to neovascular “wet” age-related macular degeneration.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

### Key References:

1. Aflibercept. In DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated February 7, 2018. Available at: <http://www.micromedexsolutions.com>. Accessed on February 23, 2018.
2. American Hospital Formulary Service® (AHFS). AHFS Drug Information 2018®. Bethesda, MD. American Society of Health-System Pharmacists®, 2018.
3. Macugen® [Product Information]. Bridgewater, NJ. Bausch & Lomb. July 2011. Available at: [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2011/021756s018lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021756s018lbl.pdf). Accessed on February 23, 2018.

PAGE 1 of 2 06/05/2018

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0289-18

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
<b>Applicable</b>	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

4. Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, et al. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2014;(11):CD008721.
5. Pegaptanib. In DrugPoints® System (electronic version). Truven Health Analytics, Greenwood, CO. Updated August 29, 2017. Available at <http://www.micromedexsolutions.com>. Accessed on February 23, 2018.
6. Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2018;(2):CD009734.
7. Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2015;(8):CD008214.
8. Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;(8):CD005139.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.